The U.K.'s Medicines and Healthcare products Regulatory Agency has allowed ReNeuron Group to start a Phase I clinical study of its stem cell treatment, which is designed to regenerate portions of the brain impaired by stroke. Called ReN001, the therapy is derived from cells from human fetal tissue and will be directly injected into the brains of 12 people between six and 24 months following their stroke.

Full Story:

Related Summaries